Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China · Delayed Price · Currency is CNY 12.97
-0.01 (-0.08%)
Sep 30, 2026, 3:04 PM CST
SHE:002900 Revenue
Harbin Medisan Pharmaceutical had revenue of 199.96M CNY in the quarter ending June 30, 2026, a decrease of -3.91%. This brings the company's revenue in the last twelve months to 805.09M, down -21.24% year-over-year. In the year 2025, Harbin Medisan Pharmaceutical had annual revenue of 789.42M, down -30.29%.
Revenue (ttm)
805.09M
Revenue Growth
-21.24%
P/S Ratio
5.10
Revenue / Employee
385.95K
Employees
2,086
Market Cap
4.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 789.42M | -343.05M | -30.29% |
| Dec 31, 2024 | 1.13B | -54.31M | -4.58% |
| Dec 31, 2023 | 1.19B | 158.37M | 15.40% |
| Jan 1, 2023 | 1.03B | 82.61M | 8.73% |
| Jan 1, 2022 | 945.80M | -393.08M | -29.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 23.66B |
| Jinling Pharmaceutical Company | 3.18B |
| Jianmin Pharmaceutical Group | 3.18B |
| Jiangsu Lianhuan Pharmaceutical | 3.00B |
| Tianjin Lisheng Pharmaceutical | 1.30B |
| LanZhou Foci Pharmaceutical | 926.49M |
| ChengDu ShengNuo Biotec | 911.15M |
| Shandong Wohua Pharmaceutical | 784.94M |